Funding for this research was provided by:
Heron Therapeutics, Inc.
Received: 1 March 2019
Accepted: 4 August 2019
First Online: 19 August 2019
Change Date: 4 February 2020
Change Type: Correction
Change Details: In Abstract, under the section ���Results���, the first and third p values are incorrect. The correct p values should be p���=���0.0004 and p���<���0.0001 respectively.
Compliance with ethical standards
: E.V. receives research Grants from Pacira and Durect and receives consulting fees from AcelRx, Avenue, Cara, Concentric, Heron, Innacoll, Mallinckrodt, Merck, Neumentum, Pacira, Pfizer, Recro, Salix, and Trevena; H.M. has received consultant fees from Heron, Durect, Pacira, Trevena, Acelrx, Cara, Sorrento, Concentric, Acacia, Recro, and Neumentum and conducted funded clinical research for Avenue, Merck, Innocoll, Durect, Pfizer and Janssen; P.W. has received investigator fees from Heron; S.R. has been on advisory boards for Heron; J.H. is an employee of Heron and receives salary and stock options; N.S. is the founder and CEO of Lotus Clinical Research, LLC, an analgesic CRO research site and consulting firm that has received study grants from Heron for the performance of clinical trial-related services.
: The study protocol was approved by the institutional review board/international ethics committee for each center.
: All the procedures performed in the study were in accordance with the ethical standards of the institutional review board/international ethics committee for each center and with the 1964 Helsinki Declaration and its later amendments.
: All the subjects included in this study provided written informed consent in accordance with the Declaration of Helsinki. The study was registered at ClinicalTrials.gov (ID NCT03237481).